Taipei Exchange - Delayed Quote TWD

Aplus Biotechnology Corporation Limited (6918.TWO)

99.20
-0.50
(-0.50%)
At close: 2:51:12 PM GMT+8
Loading Chart for 6918.TWO
  • Previous Close 99.70
  • Open 99.30
  • Bid --
  • Ask --
  • Day's Range 99.20 - 99.90
  • 52 Week Range 66.10 - 117.50
  • Volume 28,251
  • Avg. Volume 87,607
  • Market Cap (intraday) 3.026B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 20.00
  • EPS (TTM) 4.96
  • Earnings Date --
  • Forward Dividend & Yield 4.00 (4.01%)
  • Ex-Dividend Date Apr 18, 2025
  • 1y Target Est --

Aplus Biotechnology Corporation Limited engages in the development of orthopedic trauma medical equipment products. The company is based in New Taipei City, Taiwan.

www.aplusbio.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: 6918.TWO

View More

Performance Overview: 6918.TWO

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6918.TWO
27.75%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.44%

1-Year Return

6918.TWO
54.14%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
3.80%

3-Year Return

6918.TWO
62.89%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.58%

5-Year Return

6918.TWO
62.89%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
102.05%

Compare To: 6918.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6918.TWO

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    3.03B

  • Enterprise Value

    2.70B

  • Trailing P/E

    19.12

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.85

  • Price/Book (mrq)

    3.59

  • Enterprise Value/Revenue

    3.42

  • Enterprise Value/EBITDA

    11.94

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    4.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 6918.TWO

View More

Company Insights: 6918.TWO

Research Reports: 6918.TWO

View More